To assess the value of the Prostate Imaging Reporting and Data System (PI-RADS) scoring system, for prostate multiparametric magnetic resonance imaging (mpMRI) to detect prostate cancer, and classical parameters, such as prostatespecific antigen (PSA) level, prostate volume and PSA density, for predicting biopsy outcome in biopsy na€ ıve patients who have suspected prostate cancer.
Introduction
Prostate cancer is the most common male malignancy and the second most common cause of male cancer-related death [1] . Randomised trials have shown that early detection through PSA screening can alter the natural history of the disease and reduce mortality [2] . However, this benefit is associated with diagnosing many indolent tumours, for which radical treatment leads to an adverse impact on quality of life without altering survival [3] . Prostate cancer diagnosis is classically based on DRE, PSA testing, TRUS and systematic TRUS-guided biopsy. These diagnostic strategies may be associated with the increased diagnosis of many indolent tumours. TRUS is a common imaging technique used to diagnosis prostate conditions and is used during prostate biopsies. On TRUS, low-echoic lesions are typically thought to be cancer, but the sensitivity is low (range 0.17-0.57). The reported cancer detection rate with conventional prostate biopsy methods is 20-40% [4] . In addition, a prostate biopsy is costly, invasive, and associated with risks of bleeding and sepsis [5, 6] ; therefore, any non-invasive test that can reduce the likelihood of an unnecessary biopsy leading to a negative result is worth considering.
The growing availability of prostate MRI, different functional imaging modalities and increased standardisation has increased the role of prostate MRI in detecting, localising, and staging prostate cancer [7] [8] [9] . A meta-analysis that assessed the performance of multi-parametric MRI (mpMRI) for detecting prostate cancer had a specificity of 0.88, sensitivity of 0.74, and negative predictive value (NPV) of 0.64-0.94 [10] . In 2012, the European Society of Urogenital Radiology (ESUR) proposed the Prostate Imaging Reporting and Data System (PI-RADS) to detect prostate cancer with the aim of making prostate mpMRI more effective [11] . In 2015, the American College of Radiology, ESUR, and AdMeTech Foundation developed the PI-RADS scoring system version 2.0 (PI-RADS v2). A recent study using PI-RADS to predict biopsy outcome had excellent results [12] . Receiver operating characteristic (ROC) curve analysis for clinically significant prostate cancer yielded an area under the curve (AUC) of 0.89, and the NPV of a PI-RADS score of ≤2 was 0.98. However, the PI-RADS score is not perfect because the positive predictive value (PPV) for clinically significant prostate cancer was 0.49 using this threshold and 0.58 using a threshold PI-RADS score of ≤3. In addition, a few patients with a PI-RADS score of ≤2 had clinically significant prostate cancer. Therefore, other modalities to improve the predictive performance are worth considering.
The aim of the present study was to determine the predictive values of the PI-RADS v2 score combined with classical parameters, including PSA level, prostate volume, PSA density, and DRE findings with transperineal systematic and targeted biopsy as the reference standard.
Patients and Methods

Patient population
This was a retrospective observational study approved by the local Institutional Review Board. In total, 348 patients who underwent mpMRI at our hospital before a prostate biopsy, and who underwent their first prostate biopsy between July 2010 and April 2014, were included. In all, 60 patients were excluded based on the following criteria: previous prostate surgical intervention (three patients), duration between mpMRI and biopsy of >6 months (37), <14 biopsy cores taken (nine), and taking a 5a-reductase inhibitor or antiandrogen at the time of biopsy (11) . Finally, 288 patients were analysed.
MRI
All patients underwent mpMRI before biopsy using a 1.5-T (Excelart Vantage powered by Atlas; Toshiba Medical Systems, Tochigi, Japan) or 3-T (Vantage Titan 3T; Toshiba Medical Systems) machine with a 16-channel phased-array body coil. The protocol included axial and sagittal T2-weighted imaging (T2WI) and axial diffusionweighted imaging (DWI). The DWI sequences were obtained with b-values of 0, 1000, and 2000. As the currently standardised PI-RADS criteria were not in use to evaluate images at our institute when the biopsies were taken, MRI findings were reported as 'suspicious', 'equivocal' or 'normal'. However, the MRI findings were reviewed by a single uroradiologist (T.O.) blinded to the clinical details, who had 14 years of prostate MRI experience. The PI-RADS scoring system v2 was used to describe the MRI findings based on the DWI and T2WI scores. PI-RADS is described both quantitatively and qualitatively, but we used qualitative scoring only. The highest overall PI-RADS score of each mpMRI scan was used.
Prostate biopsy
The prostate biopsies were taken transperineally using an automatic biopsy gun and an 18-G needle under TRUS guidance, and general or spinal anaesthesia. In all, 14 cores (eight in the peripheral zone and six in the transitional zone) were biopsied for the systematic biopsies in all patients. Two cognitive fusion-targeted biopsy cores were added for each lesion in patients who had suspicious or equivocal lesions on mpMRI.
Clinically significant cancer
A Gleason score of ≥3 + 4 and/or a maximum cancer core length of ≥4 mm were defined as 'clinically significant prostate cancer', whereas others were defined as 'clinically insignificant prostate cancer'. This threshold was validated to predict lesions with tumour volumes of ≥0.2 mL [8, 13] .
Statistical analysis
The factors evaluated for the risk of a positive biopsy included: age, PSA level, prostate volume, PSA density, DRE findings, TRUS findings, and PI-RADS v2 score. Table 1 shows the characteristics of the study population. The median [interquartile range (IQR)] age, serum PSA level, prostate volume and PSA density values were 69 (64-74) years, 7.5 (5.5-11.0) ng/mL, 28.7 (23.3-39.4) mL, and 0.26 (0.17-0.38) ng/mL/mL, respectively. The DRE and TRUS findings were classified as 'suspicious' in 45 (16%) and 16 (6%) patients, respectively. The median (IQR) duration from mpMRI to biopsy was 1.1 (0.5-1.6) months. The 1.5-T and 3-T MRI machines were used in 118 (41%) and 170 (59%) patients, respectively.
Results
Patient data
Biopsy outcomes
In all, 159 (55%) of the 288 patients were diagnosed with prostate cancer; 141 patients were diagnosed with clinically significant prostate cancer, and 18 patients were diagnosed with clinically insignificant prostate cancer (Table 2) .
Risk factor evaluation
The ROC curve analysis for predicting total prostate cancer showed that the AUC values of prostate volume, PSA density and PI-RADS v2 score were 0.799, 0.815 and 0.835, respectively, which were higher than those for age (0.642), PSA level (0.622), DRE (0.583) and TRUS (0.543) ( Table 3 ).
The univariate logistic regression analysis showed that all factors (age, DRE findings, TRUS findings, prostate volume, total PSA level, PSA density, and PI-RADS v2 score) were significant predictors of total prostate cancer and clinically significant prostate cancer ( Table 4 ).
The PSA and prostate volume data were excluded from the multivariate analysis to avoid confounding. The multivariate logistic regression analysis revealed that PI-RADS v2 score and PSA density were independent predictors of total prostate cancer and clinically significant prostate cancer (Table 4) .
Prediction of prostate cancer
The histological outcomes stratified by PI-RADS v2 score and PSA density are shown in Figs 1A and B. When a PI-RADS v2 score of ≥3 was considered positive, the sensitivity, specificity, PPV and NPV for clinically significant prostate cancer were 0.85, 0.73, 0.75 and 0.84, respectively. Of the 131 patients with PI-RADS v2 scores of 1 or 2, 21 had clinically significant prostate cancer. We performed a subgroup analysis to identify the characteristics of the clinically significant prostate cancer classified using a PI-RADS v2 score of 1 or 2. We divided the patients with clinically significant prostate cancer into two groups: one had PI-RADS v2 scores of 1 or 2, and the other had PI-RADS v2 scores of 3-5. We compared the clinical characteristics between the two groups. The group with PI-RADS v2 scores of 1 or 2 was significantly younger, had lower PSA levels and had fewer positive biopsy cores (Table 5) . Furthermore, the group with PI-RADS v2 scores of 1 or 2 had no high-grade cancer, whereas 29% of the group with PI-RADS v2 scores of 3-5 had high-grade cancer. When the PSA density of ≥0.15 ng/mL/mL was considered positive, the sensitivity, specificity, PPV and NPV for clinically significant prostate cancer were 0.99, 0.34, 0.59 and 0.96, respectively. Of the 51 patients with a PSA density of <0.15 ng/mL/mL, only two had clinically significant prostate cancer. Figure 2 shows the detection rate of clinically significant prostate cancer using nine categories classified according to PSA density (<0.15, 0.15-0.29 or ≥0.30 ng/mL/mL) and PI-RADS v2 score (≤2, 3 or ≥4). A PI-RADS v2 score of ≥4 and a PSA density of ≥0.15 ng/mL/mL, or a PI-RADS v2 score of 3 and a PSA density of ≥0.30 ng/mL/mL (red zones), yielded the highest clinically significant prostate cancer detection rate (76-97%) and were categorised as the high-risk group. In contrast, a PI-RADS v2 score of ≤3 and PSA density of <0.15 ng/mL/mL (blue zones), yielded no clinically significant prostate cancer, which was categorised as the low-risk group. Others (green zones) yielded 20-35% detection rates for clinically significant prostate cancer, which were categorised as the moderate-risk group. The detection rates for all prostate cancer and clinically significant prostate cancer in patients categorised with low-, moderate-, and high-risk prostate cancer were 5% and 0%, 35% and 26%, and 93% and 89%, respectively (Fig. 3) . 
Prostate cancer detection after the first biopsy
Patients with negative results in their first biopsy were followed up after a median duration of 17.4 months, and there were no significant differences in follow-up duration among the groups (22.7, 15.5 and 15.4 months in the low-, moderate-and high-risk groups, respectively; P = 0.70). Of the nine patients in the high-risk group, two were diagnosed with prostate cancer after their first biopsy, and these two patients had clinically significant prostate cancer. Of the 77 patients in the moderate-risk group, five were diagnosed with prostate cancer after their first biopsy (four with clinically significant prostate cancer and one with clinically insignificant prostate cancer). In contrast, of the 42 patients in the lowrisk group, none were diagnosed with prostate cancer after their first biopsy.
Discussion
The PI-RADS v2 score was an independent predictor for both total prostate cancer and clinically significant prostate cancer and performed well as a predictor of biopsy outcome. A PI-RADS v2 score of ≥3 yielded a 0.85 sensitivity, 0.73 specificity, 0.75 PPV and 0.84 NPV for clinically significant prostate cancer. A meta-analysis that assessed the performance of mpMRI for detecting prostate cancer demonstrated specificity of 0.88 (95% CI 0.82-0.92), sensitivity of 0.74 (95% CI 0.66-0.81) and NPV of 0.64-0.94 [10] , which were comparable with our present study. Although the PI-RADS score predicts biopsy outcome well, it is difficult to decide which patients can avoid unnecessary prostate biopsies using only the PI-RADS score because of the relatively low NPV. Certainly, if patients with a PI-RADS v2 score of 1 or 2 avoided a biopsy in the present study, 16% of the clinically significant prostate cancer would have been missed. In a subgroup analysis of patients who were diagnosed with clinically significant prostate cancer, we found that patients with a PI-RADS v2 score of 1 or 2 were significantly younger, had lower PSA levels and had fewer biopsy positive cores than those with PI-RADS v2 scores of 3-5. Furthermore, patients with PI-RADS v2 scores of 1 or 2 had no high-grade cancer in contrast to patients with PI-RADS v2 scores of 3-5, of whom 29% had high-grade cancer ( Table 5 ). The prostatectomy tumour volume is associated with age, PSA and the number of positive biopsy cores, and there is a strong correlation between the Gleason score and tumour volume [14] [15] [16] [17] . Therefore, a tumour with a low volume and low-or intermediate-grade cancer may be missed or underscored by mpMRI with PI-RADS v2 scoring. However, it was also reported that the PI-RADS score yielded very high NPVs of 98-99% [12, 18] . This difference in NPV among studies may be due to differences in MRI machines, MRI protocols, variability of PI-RADS scoring, biopsy protocol, and differences in patient characteristics.
The PSA density contributes to predicting biopsy outcome [19, 20] . In the present study, PSA density was an independent predictor for total prostate cancer and clinically significant prostate cancer. When the PSA density threshold value was set to 0.15 ng/mL/mL, sensitivity, specificity, PPV and NPV for clinically significant prostate cancer were 0.99, 0.34, 0.59 and 0.96, respectively. The PSA density test performance for detecting prostate cancer has reported specificity of 0.63-0.74 and sensitivity of 0.70-0.79 when the threshold value is set to 0.15 ng/mL/mL [19, 20] . The specificity of PSA density in the present study was lower but sensitivity was higher than values reported previously. This may be due to differences in patient characteristics, biopsy protocols and/or outcome setting; i.e., clinically significant prostate cancer in the present study and total prostate cancer in previous studies. The PSA density is also useful for suggesting clinically significant prostate cancer and the aggressiveness of prostate cancer [17, [21] [22] [23] [24] . Kosaka et al. [24] reported that the PSA density was a very effective predictor of clinically significant prostate cancer in men aged ≤50 years. Furthermore, PSA density is used in the updated Epstein criteria for predicting clinically insignificant prostate cancer; the criteria are a PSA density of <0.15 ng/mL/mL, Gleason score ≤6, fewer than three positive cores, and <50% cancer involvement in any core [25] . Kund et al. [23] reported that the PSA density correlated with higher pathological staging and prostate cancer aggressiveness, such as the Gleason score and tumour volume, resulting in a decreased progression-free survival rate after radical [17] reported that PSA density was the strongest predictor of tumour upgrading in the Gleason score between initial prostate biopsy and prostatectomy. Collectively, PSA density is useful not only for predicting the biopsy outcome but also for suggesting clinically significant and aggressive prostate cancers.
Although PI-RADS and PSA density are useful for predicting biopsy outcomes, each has weaknesses; specifically, PI-RADS v2 had a relatively low NPV of 0.82, while PSA density had a low PPV of 0.59. We found that a combination of the PI-RADS v2 score and PSA density compensated for these weak points and improved the predictive performance. A PI-RADS v2 score of ≥4 and a PSA density of ≥0.15 ng/mL/mL, or a PI-RADS v2 score of 3 and a PSA density of ≥0.30 ng/mL/ mL (high-risk group), yielded the highest clinically significant prostate cancer detection rate (76-97%) (Fig. 2) . By contrast, a PI-RADS v2 score of ≤3 and a PSA density of <0.15 ng/ mL/mL (low-risk group), yielded no clinically significant prostate cancer, suggesting that patients in the low-risk group could have avoided unnecessary biopsies. Furthermore, risk stratification could help to develop a follow-up strategy. Of the patients in the high-and moderate-risk groups with negative results in their first biopsy, 22% and 7% were subsequently diagnosed with prostate cancer, respectively, whereas none in the low-risk group were diagnosed with prostate cancer. Therefore, a combination of PI-RADS v2 score and PSA density is considered very useful to predict biopsy outcome and determine the follow-up strategy for patients with negative biopsy results. Novel biomarkers that help patients to avoid unnecessary biopsies, reduce the use of interventional strategies, and enhance the risk stratification of tumours were recently developed. These biomarkers include the urine prostate cancer antigen 3 (PCA3) test, urine type 2 transmembrane serine protease with v-erythroblastosis virus E26 oncogene homolog gene fusion (TMPRSS2-ERG) status, and phosphatase and tensin homolog (PTEN) loss. In particular, the urine PCA3 score and TMPRSS2-ERG status each had significant predictive value in addition to the European Randomized Study of Screening for Prostate Cancer risk calculator for predicting prostate cancer on biopsy [26] . PTEN loss is associated with various different adverse pathological outcomes [27] . Recent immunohistochemistry studies of prostate needle biopsies found that PTEN loss predicted a poor clinical outcome and was associated with upgrading at radical prostatectomy [28, 29] . Consequently, PTEN loss in a prostate needle biopsy may be a useful marker to help stratify patients into different risk groups before definitive therapy. In the future, combining these novel biomarkers with the PI-RADS score and PSA density may better identify who can avoid unnecessary prostate biopsies or interventional procedures.
A few groups have reported that MRI combined with targeted biopsies in biopsy na€ ıve patients result in higher clinically significant cancer detection rates than those of standard TRUS biopsy [9, 30, 31] . In addition, targeted biopsy may improve the assessment of tumour grade [32] . MRI-guided bore biopsy, MRI-TRUS fusion-guided biopsy and the cognitive registration technique are three reported targeted biopsy techniques. Few studies have compared the outcomes among these three techniques. Wysock et al. [33] reported that the cancer detection rates were not significantly different between MRI-TRUS fusion and a visual estimation (cognitive fusion-targeted) biopsy. Conversely, the prospective singlecentre study by Delongchamps et al. [34] found that MRI-TRUS fusion significantly increased cancer detection rates over random biopsies, whereas cognitive fusion did not. Furthermore, a study using a TRUS prostate biopsy simulator showed that a cognitive fusion-targeted biopsy was inferior to MRI-TRUS fusion, with fewer than 50% of clinically significant prostate cancer lesions successfully sampled [35] . Certainly, two patients in the high-risk group were misses on the initial biopsy in our present study, which may be a critique of the cognitive fusion-targeted biopsy. Although the MRI-guided bore biopsy and MRI-TRUS fusion-guided biopsy have the potential to detect more clinically significant cancer using fewer cores compared with the standard biopsy technique, these methods have limited availability and are complex and costly to perform. Therefore, we performed cognitive fusion-targeted biopsy accompanied by standard TRUS biopsy. The detection rates for all prostate cancer (55%) and clinically significant prostate cancer (49%) in the present study were comparable to those of MRI-guided bore and MRI-TRUS fusion-guided biopsy series.
The strength of the present study was the relatively large number of patients, all of whom were biopsy na€ ıve and underwent mpMRI before biopsy. Furthermore, this is the first study to assess performance of the PI-RADS v2 score combined with classical predictive factors to determine biopsy outcomes.
The present study has some limitations. The analysis was retrospective, and patient selection bias may exist. Some patients underwent 1.5-T MRI, whereas others underwent 3-T MRI, reflecting ongoing technological changes at our institution. The PI-RADS v2 score was evaluated based only on T2WI and DWI. However, PI-RADS performance based on these two sequences was similar to that of other studies that have incorporated additional sequences, such as dynamic contrast-enhanced (DCE) or MR spectroscopy (MRS) [12] . In addition, the predictive performances of DCE and MRS were inferior to those of T2WI and DWI [18] . In the PI-RADS v2, DCE plays a minor role when T2WI and DWI are of diagnostic quality, and MRS is not included. Only one radiologist was involved in the MRI review, so the inter-observer reliability could not be assessed. There is no widespread accepted definition of clinically significant prostate cancer. A number of urologists were involved in taking the biopsies.
In summary, the combination of PI-RADS v2 score and PSA density could be helpful during the decision-making process before prostate biopsy and to form the follow-up strategy in biopsy na€ ıve patients. Patients with a PI-RADS v2 score of ≤3 and a PSA density of <0.15 ng/mL/mL may avoid unnecessary biopsies. These findings must be validated by prospective studies.
